Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quintiles has formed a strategic alliance agreement with the University Malaya Medical Centre (UMMC) as part of its Prime Site program which is focused on accelerating the development of new medicines.
Subscribe to our email newsletter
Quintiles said that the UMMC is the first Prime Site in Asia, adding to its existing four other sites located in the US, Europe and Africa.
Quintiles claimed that the Prime Site program is yielding impressive results in its established locations at Queen Mary’s College in London, UK, the Washington Hospital Center in Washington, DC, US, The University of Pretoria, South Africa, and the Southern California Permanente Medical Group, US.
Christopher Cabell, senior vice president of global access to patients and sites at Quintiles, said: “Prime Sites are large clinical institutions that collaborate with Quintiles to enhance their infrastructure for conducting clinical trials.
“The University Malaya Medical Centre is an ideal partner for us because of its experience in conducting clinical research, its access to substantial patient populations and its clinical expertise across multiple therapeutic areas.
“Through this new alliance, Quintiles will be able to significantly improve its reach to patients and investigators who are critical to facilitating the increasingly complex therapies under development.”
Anand Tharmaratnam, senior vice president and head of clinical development for Quintiles Asia-Pacific, said: “This, coupled with the highly skilled clinical workforce, strong clinical research infrastructure and large potential patient populations makes Malaysia and UMMC a quality fit as our first Prime Site in Asia.
“With the enthusiasm and vision for this model that our UMMC partner has shown, we are confident that this will serve as a strong foundation for our Prime Site program in Asia.”
Dato’ Ikram Shah bin Ismail, director of the University Malaya Medical Centre said: “We believe that this partnership with Quintiles will serve as an impetus for UMMC to achieve greater efficiencies in conducting clinical trials. By enhancing the efficacy, productivity and quality of clinical research at UMMC, we will ultimately propel the advancement of medical practice in improving human health.”